Sun Yanan, Chen Shanbin, Ren Fazheng, Li Yixuan
Key Laboratory of Precision Nutrition and Food Quality, Ministry of Education, Department of Nutrition and Health China Agricultural University Beijing China.
Key Laboratory of Functional Dairy, Ministry of Education, Department of Nutrition and Health China Agricultural University Beijing China.
Food Sci Nutr. 2022 Oct 20;11(1):418-427. doi: 10.1002/fsn3.3073. eCollection 2023 Jan.
Disruption of the microbial structure of intestinal bacteria due to a high-fat diet (HFD) is closely associated with metabolic disorders, such as obesity and type 2 diabetes. Probiotics are known to modulate the gut microbiota; therefore, we demonstrated the capability of N1115 (-N1115) to attenuate obesity. Four-week-old male C57BL/6J mice were fed a HFD for 12 weeks to induce obesity and were then randomized to supplemented placebo or N1115 treatment group for another 12 weeks. -N1115 treatment reduced weight gain and liver fat accumulation as well as triglyceride, total cholesterol, and low-density lipoprotein cholesterol levels. The administration of -N1115 suppressed the expression of fatty acid synthase, interleukin-1 β, and toll-like receptor 4. Notably, the operational taxonomic units that negatively and positively correlated with the obesity phenotypes were enriched and reduced, respectively, in the -N1115 treatment group. These results indicate that -N1115 attenuates obesity by modulating the gut microbiota and the expression of lipid synthesis and proinflammatory cytokine genes.
高脂肪饮食(HFD)导致的肠道细菌微生物结构破坏与肥胖和2型糖尿病等代谢紊乱密切相关。已知益生菌可调节肠道微生物群;因此,我们证明了N1115(-N1115)减轻肥胖的能力。给四周龄雄性C57BL/6J小鼠喂食HFD 12周以诱导肥胖,然后随机分为补充安慰剂组或N1115治疗组,再持续12周。-N1115治疗减少了体重增加和肝脏脂肪积累,以及甘油三酯、总胆固醇和低密度脂蛋白胆固醇水平。-N1115的给药抑制了脂肪酸合酶、白细胞介素-1β和Toll样受体4的表达。值得注意的是,与肥胖表型呈负相关和正相关的操作分类单元在-N1115治疗组中分别得到了富集和减少。这些结果表明,-N1115通过调节肠道微生物群以及脂质合成和促炎细胞因子基因的表达来减轻肥胖。